Hoda, Mir Alireza

Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders

Kornauth, C., Pemovska, T., Vladimer, G. I., Bayer, G., Bergmann, M., Eder, S., Eichner, R., Erl, M., Esterbauer, H., Exner, R., et al. (2022) · Cancer Discovery

Acute Myeloid Leukemia ResearchChronic Lymphocytic Leukemia Research

Cited by 206

Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors

Torok, S., Rezeli, M., Kelemen, O., Vegvari, A., Watanabe, K., Sugihara, Y., Tisza, A., Marton, T., Kovacs, I., Tovari, J., et al. (2017) · Theranostics

Angiogenesis and VEGF in CancerMass Spectrometry Techniques and Applications

Cited by 70

KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy

Ghimessy, Á. K., Gellert, Á., Schlegl, E., Hegedus, B., Raso, E., Barbai, T., Timar, J., Ostoros, G., Megyesfalvi, Z., Gieszer, B., et al. (2019) · Cancers

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 27

Circulating Activin A Is a Novel Prognostic Biomarker in Malignant Pleural Mesothelioma—A Multi-Institutional Study

Hoda, M. A., Dong, Y., Rozsas, A., Klikovits, T., Laszlo, V., Ghanim, B., Stockhammer, P., Ozsvar, J., Jakopovic, M., Samarzija, M., et al. (2016) · European Journal of Cancer

Occupational and environmental lung diseasesTGF-β signaling in diseases

Cited by 27